Drugs / Sulopenem-Etzadroxil/Probenecid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03357614 | Sep 2018 → Dec 2019 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulopenem-Etzadroxil/Probenecid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03357614 ↗ |
| Route | Oral | “sulopenem-etzadroxil/probenecid 500 mg PO twice daily” NCT03357614 ↗ |